ChemoCentryx, Inc. (CCXI) Upgraded at Zacks Investment Research
ChemoCentryx, Inc. (NASDAQ:CCXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The brokerage presently has a $12.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price would indicate a potential upside of 20.24% from the company’s current price.
According to Zacks, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California. “
ChemoCentryx (CCXI) traded down 4.86% during trading on Monday, hitting $9.98. The stock had a trading volume of 332,818 shares. The company’s market cap is $480.77 million. ChemoCentryx has a 52 week low of $3.95 and a 52 week high of $10.68. The stock has a 50-day moving average price of $7.46 and a 200-day moving average price of $7.33.
ChemoCentryx (NASDAQ:CCXI) last released its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.14. The company had revenue of $8.23 million during the quarter. Equities analysts predict that ChemoCentryx will post ($0.69) EPS for the current year.
In related news, insider Petrus Bekker sold 76,013 shares of the stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $9.95, for a total value of $756,329.35. Following the completion of the transaction, the insider now owns 65,963 shares of the company’s stock, valued at $656,331.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roger C. Lucas sold 4,000 shares of the stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $7.31, for a total transaction of $29,240.00. Following the completion of the transaction, the director now directly owns 62,822 shares of the company’s stock, valued at approximately $459,228.82. The disclosure for this sale can be found here. Insiders sold 225,399 shares of company stock valued at $2,163,943 in the last three months. Company insiders own 26.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of CCXI. Franklin Resources Inc. raised its position in ChemoCentryx by 22.4% in the first quarter. Franklin Resources Inc. now owns 2,165,397 shares of the biopharmaceutical company’s stock valued at $5,392,000 after buying an additional 396,900 shares during the period. California State Teachers Retirement System raised its position in ChemoCentryx by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 51,873 shares of the biopharmaceutical company’s stock valued at $420,000 after buying an additional 984 shares during the period. Baker BROS. Advisors LP acquired a new position in ChemoCentryx during the third quarter valued at about $296,000. Goldman Sachs Group Inc. raised its position in ChemoCentryx by 243.2% in the first quarter. Goldman Sachs Group Inc. now owns 66,714 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 47,275 shares during the period. Finally, Vivo Capital LLC acquired a new position in ChemoCentryx during the first quarter valued at about $2,211,000. 49.37% of the stock is owned by hedge funds and other institutional investors.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.